The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Innate Immunity in Multiple Sclerosis: Myeloid Dendritic Cells in Secondary Progressive Multiple Sclerosis Are Activated and Drive a Proinflammatory Immune Response
Open accessAbstract
Multiple sclerosis (MS) is postulated to be a T cell-mediated autoimmune disease characterized clinically by a relapsing-remitting (RR) stage followed by a secondary progressive (SP) phase. The progressive phase is felt to be secondary to neuronal degenerative changes triggered by inflammation. The status of the innate immune system and its relationship to the stages of MS is not well understood. Dendritic cells (DCs) are professional APCs that are central cells of the innate immune system and have the unique capacity to induce primary immune responses. We investigated circulating myeloid DCs isolated directly from the blood to determine whether there were abnormalities in myeloid DCs in MS and whether they were related to disease stage. We found that SP-MS subjects had an increased percentage of DCs expressing CD80, a decreased percentage expressing PD-L1, and an increased percentage producing IL-12 and TNF-α compared with RR-MS or controls. A higher percentage of DCs from both RR and SP-MS patients expressed CD40 compared with controls. We then investigated the polarization effect of DCs from MS patients on naive T cells taken from cord blood using a MLR assay. Whereas DCs from RR-MS induced higher levels of Th1 (IFN-γ, TNF-α) and Th2 (IL-4, IL-13) cytokines compared with controls, DCs from SP-MS only induced a polarized Th1 response. These results demonstrate abnormalities of DCs in MS and may explain the immunologic basis for the different stages and clinical patterns of MS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Nature of the Principal Type 1 Interferon-Producing Cells in Human Blood
Siegal, F. P., Kadowaki, N., Shodell, M., Fitzgerald-Bocarsly, P. A., Shah, K., Ho, S., Antonenko, S., & Liu, Y.-J. (1999) · Science · doi:10.1126/science.284.5421.1835 · Cited by 2,293
Immunology of multiple sclerosis
Sospedra, M., & Martin, R. (2005) · Annual Review of Immunology · doi:10.1146/annurev.immunol.23.021704.115707 · Cited by 2,149
Exacerbations of multiple sclerosis in patients treated with gamma interferon
Panitch, H., Haley, A., Hirsch, R., & Johnson, K. (1987) · The Lancet · doi:10.1016/s0140-6736(87)92863-7 · Cited by 1,071 · cited 1×
“This may be relevant to MS given the evidence that viral activation may trigger MS relapses (38) as does systemic administration of IFN- (39).”
BackgroundDendritic cells permit immune invasion of the CNS in an animal model of multiple sclerosis
Greter, M., Heppner, F. L., Lemos, M. P., Odermatt, B. M., Goebels, N., Laufer, T., Noelle, R. J., & Becher, B. (2005) · Nature Medicine · doi:10.1038/nm1197 · Cited by 862 · cited 6×
“It is known that T cells play a central role in the earlier stages of the disease process, because blocking of T cell entry into the brain in RR-MS with anti-VLA-4 Ab markedly decreases MS attacks and CNS inflammation as measured by gadolinium enhancing lesions (38).”
BackgroundInfluentialEpitope spreading initiates in the CNS in two mouse models of multiple sclerosis
McMahon, E. J., Bailey, S. L., Castenada, C. V., Waldner, H., & Miller, S. D. (2005) · Nature Medicine · doi:10.1038/nm1202 · Cited by 694 · cited 6×
“It is known that T cells play a central role in the earlier stages of the disease process, because blocking of T cell entry into the brain in RR-MS with anti-VLA-4 Ab markedly decreases MS attacks and CNS inflammation as measured by gadolinium enhancing lesions (38).”
BackgroundInfluentialBjartmar, C., Wujek, J. R., & Trapp, B. D. (2003) · Journal of the Neurological Sciences · doi:10.1016/s0022-510x(02)00069-2 · Cited by 573
Serafini, B., Rosicarelli, B., Magliozzi, R., Stigliano, E., Capello, E., Mancardi, G. L., & Aloisi, F. (2006) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/65.2.124 · Cited by 176
Cited by
Multiple Sclerosis: Mechanisms and Immunotherapy
Baecher-Allan, C., Kaskow, B. J., & Weiner, H. L. (2018) · Neuron · doi:10.1016/j.neuron.2018.01.021 · Cited by 938
Self-citationDendritic cell migration in health and disease
Worbs, T., Hammerschmidt, S. I., & Förster, R. (2017) · Nature Reviews Immunology · doi:10.1038/nri.2016.116 · Cited by 827
The role of dendritic cells in autoimmunity
Ganguly, D., Haak, S., Sisirak, V., & Reizis, B. (2013) · Nature Reviews Immunology · doi:10.1038/nri3477 · Cited by 507
The immunology of multiple sclerosis
Attfield, K. E., Jensen, L. T., Kaufmann, M., Friese, M. A., & Fugger, L. (2022) · Nature Reviews Immunology · doi:10.1038/s41577-022-00718-z · Cited by 380
Venken, K., Hellings, N., Thewissen, M., Somers, V., Hensen, K., Rummens, J., Medaer, R., Hupperts, R., & Stinissen, P. (2008) · Immunology · doi:10.1111/j.1365-2567.2007.02690.x · Cited by 360
The challenge of multiple sclerosis: How do we cure a chronic heterogeneous disease?
Weiner, H. L. (2009) · Annals of Neurology · doi:10.1002/ana.21640 · Cited by 344
Self-citationRole of the innate immune system in the pathogenesis of multiple sclerosis
Gandhi, R., Laroni, A., & Weiner, H. L. (2010) · Journal of Neuroimmunology · doi:10.1016/j.jneuroim.2009.10.015 · Cited by 331
Self-citationNeutrophil-related factors as biomarkers in EAE and MS
Rumble, J. M., Huber, A. K., Krishnamoorthy, G., Srinivasan, A., Giles, D. A., Zhang, X., Wang, L., & Segal, B. M. (2015) · Journal of Experimental Medicine · doi:10.1084/jem.20141015 · Cited by 262
Circulating MicroRNAs as biomarkers for disease staging in multiple sclerosis
Gandhi, R., Healy, B., Gholipour, T., Egorova, S., Musallam, A., Hussain, M. S., Nejad, P., Patel, B., Hei, H., Khoury, S., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23880 · Cited by 258
Self-citationWeiner, H. L. (2008) · Journal of Neurology · doi:10.1007/s00415-008-1002-8 · Cited by 255
Self-citationAdaptive immunity affects learning behavior in mice
Brynskikh, A., Warren, T., Zhu, J., & Kipnis, J. (2008) · Brain, Behavior, and Immunity · doi:10.1016/j.bbi.2007.12.008 · Cited by 221
“Although activated T cells release cytokines that could affect neuronal function (Karni et al., 2006), the state of T cell activation in the CNS following trans-endothelial migration is debatable (Flugel et al., 2001).”
BackgroundAn emerging role for eotaxins in neurodegenerative disease
Huber, A. K., Giles, D. A., Segal, B. M., & Irani, D. N. (2018) · Clinical Immunology · doi:10.1016/j.clim.2016.09.010 · Cited by 133
The TNF-α System: Functional Aspects in Depression, Narcolepsy and Psychopharmacology
Berthold-Losleben, M., & Himmerich, H. (2008) · Current Neuropharmacology · doi:10.2174/157015908785777238 · Cited by 119
Dysregulation of regulatory CD56bright NK cells/T cells interactions in multiple sclerosis
Laroni, A., Armentani, E., Kerlero de Rosbo, N., Ivaldi, F., Marcenaro, E., Sivori, S., Gandhi, R., Weiner, H. L., Moretta, A., Mancardi, G. L., et al. (2016) · Journal of Autoimmunity · doi:10.1016/j.jaut.2016.04.003 · Cited by 112
Self-citationGharibi, T., Ahmadi, M., Seyfizadeh, N., Jadidi-Niaragh, F., & Yousefi, M. (2015) · Cellular Immunology · doi:10.1016/j.cellimm.2015.01.002 · Cited by 104
Inhibition of CD40L with frexalimab in multiple sclerosis
Vermersch, P., Granziera, C., Mao-Draayer, Y., Cutter, G., Kalbus, O., Staikov, I., Dufek, M., Saubadu, S., Bejuit, R., Truffinet, P., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2309439 · Cited by 102
Gillen, K. M., Mubarak, M., Nguyen, T. D., & Pitt, D. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00255 · Cited by 88
Metadata
- Authors
- Karni, A., Abraham, M., Monsonego, A., Cai, G., Freeman, G. J., Hafler, D., Khoury, S. J., & Weiner, H. L.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2006-09
- Volume
- 177
- Issue
- 6
- Pages
- 4196-4202
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2106980391
- Cited by
- 177
- References
- 7
- FWCI
- 6.25
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.